The investigation targets potential breaches of fiduciary duty by the board of the Ramsey, New Jersey-based biopharmaceutical firm. Attorneys Andrew Abramowitz and Caitlin Adorni are leading the inquiry, inviting shareholders to disclose information regarding the company's sales practices for its primary intravenous immune globulin therapy, which treats Primary Humoral Immunodeficiency.
Berger Montague, a firm with a history of complex class-action litigation, is seeking to determine if leadership prioritized short-term revenue gains over transparent reporting. Investors holding ADMA stock may contact the firm directly to discuss the legal implications of these allegations or to participate in the ongoing review of the company's recent financial disclosures.
Comments (0)
No comments yet. Be the first!